The clinical measurement, measurement method and experimental condition ontologies: expansion, improvements and new applications by unknown
JOURNAL OF
BIOMEDICAL SEMANTICS
Smith et al. Journal of Biomedical Semantics 2013, 4:26
http://www.jbiomedsem.com/content/4/1/26RESEARCH Open AccessThe clinical measurement, measurement method
and experimental condition ontologies:
expansion, improvements and new applications
Jennifer R Smith1, Carissa A Park2, Rajni Nigam1, Stanley JF Laulederkind1, G Thomas Hayman1, Shur-Jen Wang1,
Timothy F Lowry1, Victoria Petri1, Jeff De Pons1, Marek Tutaj1, Weisong Liu1, Elizabeth A Worthey1,3,
Mary Shimoyama1,4* and Melinda R Dwinell1,5Abstract
Background: The Clinical Measurement Ontology (CMO), Measurement Method Ontology (MMO), and
Experimental Condition Ontology (XCO) were originally developed at the Rat Genome Database (RGD) to
standardize quantitative rat phenotype data in order to integrate results from multiple studies into the PhenoMiner
database and data mining tool. These ontologies provide the framework for presenting what was measured, how it
was measured, and under what conditions it was measured.
Results: There has been a continuing expansion of subdomains in each ontology with a parallel 2–3 fold increase
in the total number of terms, substantially increasing the size and improving the scope of the ontologies. The
proportion of terms with textual definitions has increased from ~60% to over 80% with greater synchronization of
format and content throughout the three ontologies. Representation of definition source Uniform Resource
Identifiers (URI) has been standardized, including the removal of all non-URI characters, and systematic versioning of
all ontology files has been implemented. The continued expansion and success of these ontologies has facilitated
the integration of more than 60,000 records into the RGD PhenoMiner database. In addition, new applications of
these ontologies, such as annotation of Quantitative Trait Loci (QTL), have been added at the sites actively using
them, including RGD and the Animal QTL Database.
Conclusions: The improvements to these three ontologies have been substantial, and development is ongoing.
New terms and expansions to the ontologies continue to be added as a result of active curation efforts at RGD and
the Animal QTL database. Use of these vocabularies to standardize data representation for quantitative phenotypes
and quantitative trait loci across databases for multiple species has demonstrated their utility for integrating diverse
data types from multiple sources. These ontologies are freely available for download and use from the NCBO
BioPortal website at http://bioportal.bioontology.org/ontologies/1583 (CMO), http://bioportal.bioontology.org/
ontologies/1584 (MMO), and http://bioportal.bioontology.org/ontologies/1585 (XCO), or from the RGD ftp site at
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Integrating phenotype data from multiple experiments
and sources is challenging because of the general lack of
standardization in how such data is presented. The
Clinical Measurement (CMO), Measurement Method
(MMO), and Experimental Condition (XCO) Ontologies
were developed at the Rat Genome Database (RGD)
[1-3] to meet this challenge [4]. The CMO, MMO, and
XCO constitute a suite of ontologies designed to provide
detailed descriptions of specific, quantitative phenotype
data and the experiments that produced them by indi-
cating (1) what was measured, (2) how it was measured,
and (3) under what conditions it was measured. Along
with the Rat Strain Ontology, these form the basis of the
RGD PhenoMiner tool for mining and visualizing quan-
titative phenotype data [5].
Because the ontologies were designed to work to-
gether, their development was originally, and continues
to be, coordinated. They were first used to integrate and
standardize high-throughput rat phenotype data from
the PhysGen Programs for Genomic Applications (PGA)
[6,7] and the National BioResource Project for the Rat in
Kyoto, Japan (NBRP) [8], and by the COVER project at
Washington University in St. Louis in the integration of
human cardiovascular phenotype data [4]. The success
of these efforts has prompted further development of
these ontologies, resulting in expansions of their size,
their scope, and their usage. This paper will present
details regarding these improvements to the ontologies
and information about applications of the ontologies
which have recently been implemented.
Results and discussion
Increases in the size and scope of the clinical
measurement ontology
As stated when this ontology was originally released, the
Clinical Measurement Ontology was “…primarily orga-
nized on the highest level according to the body system
in which the measurement is made” [4]. This is still theTable 1 Comparison of ontology statistics between 2012 and
Clinical measurement
2012 2013
Total # terms 523 1691
Defined terms 328 1427
Percent defined 62% 84%
Maximum depth 7 11
% terms with 2 or more parents 2.0% 15.8%
% terms with single subclass 10.3% 15.6%
Average branching factor 0.98 0.86
Table 1 displays the total number of terms for each ontology as well as the numbe
original publication in May 2012 and as of July/August 2013. In addition, basic stati
degree of branching for each are included.case. However, both the size and the scope of the ontol-
ogy have substantially increased [9]. Between 2012 and
2013, the number of terms has grown from a total of
523 to 1691, the maximum depth of the ontology has
now increased to 11, the percentage of classes with a
single subclass is 15.6%, and the average branching
factor is 0.86 (Table 1). This table also shows that the
percentage of classes with two or more parents has in-
creased to 15.8%. Although it is a common practice to
limit the number of asserted parents to a single one for
each ontology term, the applications for which these
ontologies were designed are largely geared toward
physiological and clinical researchers. As such and in
keeping with our decision from the beginning to use a
pragmatic approach to the design of these ontologies, in
cases where it seems clear that a researcher would
expect to find a relationship between terms it is our
practice to assert that parentage. Also, as will be
discussed later, we have found that some groups have
begun to extract only a small subset of terms from one
of these ontologies, to use according to their needs. This
practice is facilitated by the assertion of parentage rather
than limiting those assertions to a single parent and
trusting semantic reasoners to supply the missing rela-
tionships. For these applications, artificially limiting the
assertions of parentage or conforming to a formalized
ontology design pattern (ODP) or structured upper level
ontology such as the Basic Formal Ontology (BFO),
while perhaps improving the ontology’s logical structure,
renders the ontology opaque to many researchers’
attempts to browse the vocabulary to find the term(s)
they need. In this respect, as Lord and Stevens com-
mented, “…while realist principles may enable straight-
forward modelling for some topics, there are crucial
aspects of science and the phenomena it studies that do
not fit into this approach; realism appears to be over-
simplistic which, perversely, results in overly complex
ontological models” [10]. The structures of the ontolo-
gies are therefore based on their contents and the2013
Measurement method Experimental condition
2012 2013 2012 2013
195 402 110 346
116 326 76 320
59% 81% 69% 92%
6 8 5 8
<1% 7.2% 1.0% 14.2%
7.7% 14.9% 10.9% 17.1%
1.00 0.93 0.99 0.87
r and percentage of those terms with textual definitions, at the time of the
stics such as the maximum depth of each ontology and information about the
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research communities that are using the vocabularies.
As shown in Table 2 and Figure 1A, the scope has
expanded from 13 direct subclasses of the term “clinical
measurement” to 26. The new branches include coverage
for additional organ systems (alimentary/gastrointestinal
system, endocrine/exocrine system, immune system, mus-
culoskeletal system, nervous system, and skin) as well as
coverage for measurements that do not necessarily come
to mind as “phenotypes”. These include branches related
to disease population measurements such as incidence
and prevalence, to disease processes such as onset/diagno-
sis and progression, and to mortality and survival. In these
cases, quantitative values are commonly assessed and
reported in the literature. For example, researchers will
give a number for the percentage of a study population
that develop a disease within a given period of time, report
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Table 2 lists all of the direct children of the parent CMO term “clinical
measurement” as of July 2013, v2.5. These are divided into the list of terms
that existed at the time of the original publication of the ontology on the left
and those which have subsequently been added to the ontology on the right.
Increases in the scope of the CMO have almost doubled the number of direct
subclasses of the parent.proportion of animals in a study population which are
surviving at a series of time points.
A branch for chemical response and sensitivity mea-
surements which covers the results of a variety of both
in vivo and ex vivo drug and chemical tests was added,
as was a branch for “exudate measurements” for use
with measurements made on extravasated fluid or other
substances.
The term originally labeled as “organ measurement”
(CMO:0000068) was changed to “organ morphological
measurement” in keeping with its placement under
“body morphological measurement” and above terms
which described only organ morphology. A new term for
“organ measurement” (CMO:0000669) was created
directly under the root term “clinical measurement” and
linked as a parent to “organ morphological measure-
ment” (CMO:0000068) (Figure 1B). These changes have
allowed inclusion of physiological measurements related
to the specified organs in addition to their correspond-
ing morphological measurements.
A new branch for “body movement measurement”
addresses a common area of study in rodent research
that was not covered in the earlier version of the CMO.
This branch is designed to include both involuntary
movements, such as measurement of the acoustic startle
response (CMO:0001519), and voluntary movements. In
the rodent research literature, measurements of volun-
tary movements such as locomotor behavior in an open
field apparatus, rearing, or freezing are often presented
as measurements of the emotional state of the animal
(e.g., anxiety [11]). Although this is a common inter-
pretation of the results, the psychological state is not
the actual quantity being measured. Additionally, such
movement measurements can be used in other con-
texts. A cursory search of the rat literature resulted
in articles in which movement in an open field appa-
ratus was used to assess learning/memory [12],
ethanol-related hyperactivity [13], the sedative effects
of drug treatments [14], the locomotor effects of ves-
tibular dysfunction [15], and the effects of cholinergic
denervation of the hippocampus [16]. This being the case,
the branch was developed as representing measurements
of movement in general, not of psychology or emotional-
ity. Also, because the same measurements are made across
a number of different types of apparatus, the specifics of
the apparatus are assigned via the MMO rather than being
included in the CMO terms.
Collaboration with the Animal QTL Database (QTLdb)
[17,18] has led to the addition of a substantial number of
CMO terms related to agricultural animal assessments.
These include terms for measurements commonly used
by the agricultural community to assess the composition
and yield of milk for cattle and sheep, as well as measure-
ments of fowl eggs, of fat and muscle morphology and fat
2012: 13 direct 
children of "clinical 
measurement"
2013: 26 direct 




Figure 1 The clinical measurement ontology 2012 vs. 2013. A. Additions and improvements to the CMO have resulted in an expansion of
both the number of terms and the scope of the ontology. In May of 2012, there were 13 direct child terms under the root “clinical
measurement”. As of July 2013, this had increased to 26. The vertical arrows point to the level in the display which corresponds to the vocabulary
nodes directly under the root. B. Adjustments to the branch for “body morphological measurement” and addition of a new branch for “organ
measurement” clarified the morphological terms and allowed for addition of organ-specific physiological terms.
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weight gain in cattle, pigs, sheep, and chickens.
Increases in the size and scope of the measurement
method ontology
The Measurement Method Ontology covers the domain
of the specific methods used to make the measurements
represented by the CMO terms, i.e., “how it was mea-
sured”. This being the case, development of this ontol-
ogy is closely coordinated with the development of the
CMO and it has likewise increased in size and scope
[19]. The number of terms in the MMO has increased
from 195 to 402, the maximum depth of the ontology
has increased to 8, the percentage of classes with two or
more parents has risen to 7.2%, the percentage of classeswith a single subclass is 14.9%, and the average
branching factor is 0.93 (Table 1). The MMO is sub-
divided into two major branches: “in vivo method” for
methods performed in or on a living body, and “ex vivo
method” for procedures performed outside the living
body. Improvements to the in vivo branch include the
addition of terms for body movement methods, such as
subbranches for types of test enclosures, mazes, and
treadmills, and addition of more general branches for
“flowmetry” and “body fluid collection method”. New
subbranches under “ex vivo method” include radioacti-
vity and volume measurement methods, as well as a
branch for “isolated cell method” which corresponds to
expansion of the CMO “cell measurement” branch. In
several cases, what was originally a single term has been
Smith et al. Journal of Biomedical Semantics 2013, 4:26 Page 5 of 12
http://www.jbiomedsem.com/content/4/1/26expanded into a larger branch. For instance “gel electro-
phoresis”, originally a direct child of “ex vivo method”,
now appears within the “molecular separation method”
branch of the MMO (Figure 2).
Increases in the size and scope of the experimental
condition ontology
Because incorporation of data from new areas of re-
search requires the addition of new condition terms, the
Experimental Condition Ontology has expanded from
110 to 346 terms, the maximum depth of the ontology
has now increased to 8, the percentage of classes with
two or more parents is 14.2%, the percentage of classes
with a single subclass is 17.1% and the average bran-
ching factor is 0.87 (Table 1) [20]. New branches under
“experimental condition” include “controlled visible light
condition”, “controlled in situ organ condition” and
“pathogen”. New terms include “sample resting period”,
which was necessitated by experiments in which sepa-
rate measurements were made on a sample before and
after the sample was allowed to sit for a specified period
of time. The only difference in the conditions between
the two values was the “sample resting period”. In
addition, a term for “perfusate” was added within the
more general “solution” branch to describe experiments
performed on isolated organs. The terms “surgical im-
plantation” and “surgical removal” were moved under the
new “surgical manipulation” term, and “fasting” was incor-
porated into the existing “diet” branch.
The most extensive additions to the XCO were made in
the existing “chemical” branch. Originally, the branchFigure 2 The measurement method ontology 2012 vs. 2013. Addition
“molecular separation method” branch under “ex vivo method”. The term “
moved from being a direct child of “ex vivo method” into the new branchincluded four subclasses: “anesthetic”, “neoplasm inducing
agent”, “polycyclic arene”, and “steroid”. As the number of
subclasses increased (at one point reaching 25 direct
children of “chemical”) it became clear that a better
organizational strategy was needed. Table 3 compares the
original children of “chemical” with the current structure
of the branch. Following the lead of the Chemical Entities
of Biological Interest (ChEBI) ontology [21,22], the branch
was split into two major subbranches: “chemical with
specified function” and “chemical with specified struc-
ture”. Classes representing functional roles such as
“disease inducing chemical” and “neurotransmitter” have
been moved under the former term. Those representing
structural classifications such as “hydrocarbon” and “sul-
fonamide” are now found under the latter. This structure
facilitates browsing for researchers. In this way, whether a
chemist is looking for a nitrosourea or a physiologist is
looking for a mutation inducing agent both will find the
commonly used mutagen N-ethyl-N-nitrosourea (ENU)
where they would intuitively expect it to be. Note that the
term “polycyclic arene”, previously a direct child of “che-
mical”, has been moved to the appropriate level within the
more general “hydrocarbon” subbranch. Where possible,
the corresponding ChEBI ID is given as a cross-reference
for the term in the XCO.
Consideration was given to simply using the ChEBI
ontology for chemical conditions. However, ChEBI is
fundamentally an ontology of chemical structures. We
would argue that the concept of the use of a chemical as
an experimental condition is qualitatively different than
that of a chemical as a structure or molecule. Inof new terms such as “chromatography” necessitated the creation of a
gel electrophoresis”, as a type of molecular separation method, was
.
Table 3 Expansion of the “chemical” branch of the
experimental condition ontology
Original subclasses of
“chemical” in the XCO
Current organization of terms under
“chemical” in the XCO
Anesthetic Chemical with specified function





























Table 3 highlights the expansion and reorganization of the XCO branch under
the subclass “chemical”. The original four subclasses are shown on the left. As
of August 2013, v3.0, the branch has been divided into two major
subcategories: “chemical with specified function” and “chemical with specified
structure” and the terms which were previously direct children of “chemical”
have been moved under one of these two. In addition to more closely
following the familiar structure of the ChEBI ontology, the new organization
facilitates browsing.
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level gene-chemical interactions which differs from an
annotation of a chemical bolus or solution being adminis-
tered as an experimental stressor. The decision was there-
fore made to include terms for chemical conditions in the
XCO and express the relationship between such a condi-
tion and the structure and role of the referenced chemical
via cross references to the appropriate ChEBI ID.Improvements to textual definitions
Work is currently ongoing to both increase the propor-
tion of terms with textual definitions and standardize
the format of those definitions for all three ontologies.
As shown in Table 1, at the time of the original publica-
tion 62% (328/523) of CMO, 59% (116/195) of MMO,
and 69% (76/110) of XCO terms had assigned defini-
tions. This proportion has increased to 84% (1427/1691),
81% (326/402), and 92% (320/346), respectively.
As terms are defined, definitions for words or phrases
that will be reused are added to a growing list of stan-
dardized definition “fragments”. Definitions are currently
written manually rather than being automatically gene-
rated, but the structure is based on the standard genus-
differentia model so that the definition of the child
includes the definition of the parent with the addition of
applicable differentiating information. As much as pos-
sible, each definition is written in such a way that it
“stands alone”, that is, so that the user is not required to
go up the tree to find the definition of the more general
concept. In this way, the definition of “plasma glucose
level” (CMO:0000042) has been expanded from “The
level of glucose found in a specific volume of plasma” to
“Measurement of the amount of glucose, the monosac-
charide sugar, C6H12O6, occurring widely in plant and
animal tissues which is one of the three dietary monosac-
charides that are absorbed directly into the bloodstream
during digestion, is the end product of carbohydrate
metabolism, and is the chief source of energy for living
organisms, in a specified volume of plasma, the fibrinogen-
containing fluid portion of the blood in which the particu-
late components are suspended” in order to incorporate
the fragments which define level, glucose, and plasma,
respectively. A list of the standard definition fragments
currently in use is provided as Additional file 1.
Additional improvements
Additional improvements have been implemented to
bring the development of the three ontologies into line
with established best practices [23]. Because the develop-
ment of these ontologies was carried out collaboratively,
over time textual information such as definition source
Uniform Resource Identifiers (URI) was entered using a
variety of formats. For instance, at one point “Dorland’s
Illustrated Medical Dictionary, 31st Edition” [24], one of
a number of sources used frequently for all three ontol-
ogies, was represented by 14 slightly different URIs,
most of which differed by as little as the inclusion of a
period or apostrophe, or the designation of the edition.
Although such differences are simple for the human
mind to interpret, they make the information difficult to
interpret by parsers and other computer applications.
These have all been standardized to “Dorland:Dorlands_
Illustrated_Medical_Dictionary–31st_Ed”. As this example
Table 4 QTLs annotated with CMO terms at the animal
QTLdb









Cattle 3431 7117 48.2%
Pig 2933 8402 34.9%
Chicken 2315 3808 60.8%
Sheep 320 789 40.6%
Rainbow trout 78 127 61.4%
Total 9077 20243 44.8%
Table 4 lists the number by species and the total number of QTLs which have
been associated with any term from the Clinical Measurement Ontology at the
Animal QTLdb as of July 2013.
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tted to remove all “non-URI” characters as defined by the
World Wide Web Consortium (W3C) [25]. According to
the W3C document, the characters permitted for a URI
which do not have a reserved purpose include upper- and
lowercase letters (A-Z/a-z), digits (0–9), hyphen, period,
underscore, and tilde. All definition source URIs for the
CMO, MMO, and XCO have been reformatted so that
only those characters are used. Also, to further increase
the standardization and traceability of definitions, the
applicable ISBN number has been added to the list of
source URIs when a hard-copy book is used rather than
an online resource. A representative list of definition
source URIs has been provided as Additional file 2.
Finally, a standardized system for file versioning has
been implemented, including minor version increments
for ongoing term and definition additions and major
version increments for global changes to the contents or
structure of the ontologies. For example, the standar-
dization of the definition source URIs was considered a
global change to the contents of the ontologies and
warranted the increase of the major version number for
each ontology from 1.x to 2.0. The current version num-
ber for each ontology can be found as the “data-version”
notation in the header of the ontology file (See Additional
file 3). The data version for each file is also given in the list
of ontology files available on the applicable NCBO
BioPortal ontology page. The version numbers referenced
in this paper are v2.5 for the CMO, v2.3 for the MMO,
and v3.0 for the XCO.
Expanded applications
Successful use of the three ontologies for their original
intent has spurred expansion into new areas. The
Animal QTLdb has instituted the use of the CMO, map-
ping existing QTL trait descriptions to measurement
terms. The CMO term is used alone or in conjunction
with the Vertebrate Trait Ontology (VT) [26] and/or the
Product Trait Ontology [27] to cover the various con-
cepts represented by the original Animal Trait Ontology
(ATO) [28]. Currently, over 600 ATO traits have been
mapped to 267 unique CMO terms, and a total of 9077
animal QTL and SNP association data have been anno-
tated using the CMO (Table 4).
RGD has substantially expanded its use of the CMO,
MMO, and XCO for integration of complex datasets in
the PhenoMiner project. The number of averaged or
summary records in the PhenoMiner database has
increased from approximately 13,000 in May, 2012 to
now over 69,000. This includes incorporation of
additional high-throughput data from the PGA and the
PhysGen Knockout project for the rat [29] as well as
records derived from manual review of the literature to
find and integrate quantitative phenotype data. Suchdata was previously difficult to locate, because it is often
dispersed in tables, text, figures, and figure legends
incorporated in the body of the paper or included with
the supplementary data, and was even more difficult to
compare across studies. Easy access to consolidated
results across rat strains and experiments is now
available in the RGD PhenoMiner tool [30]. Results for a
single strain can be accessed directly in PhenoMiner or
from the strain phenotype profile section, labelled
“Phenotype Values via PhenoMiner”, on the RGD strain
report page. All CMO terms for which data exists in the
PhenoMiner database are listed and terms link to the
corresponding data in the tool display (Figure 3).
High-throughput phenotyping projects such as the
PGA often store the quantitative data from each
individual rat that is tested. When such data is available
each individual measurement is stored separately in the
PhenoMiner database, in addition to being grouped and
averaged to form a subset of the aforementioned summary
records. Currently the number of individual records is
over 563,000.
CMO, MMO, XCO, VT, and Rat Strain (RS) ontology
terms are also assigned to QTL records at RGD
(Figure 4) with over 80% (1578/1911) of RGD’s rat QTLs
annotated to date. This provides clear experimental de-
sign information to users, allows the user to examine,
query, and group data by experimental parameters, and
links specific sites on the rat genome to the quantitative
measurement data in PhenoMiner.
In addition to extraction of phenotype data from the
literature by curators, researchers who carry out pheno-
typing projects on rat strains are encouraged to submit
their data directly to RGD. A submission form has been
posted on the RGD website to facilitate the process [31].
Researchers collaborate with RGD staff members during
the submission process to ensure that their data is
integrated into the resource correctly and in a timely
fashion.
Figure 3 Access to strain-specific quantitative phenotype data from RGD strain report pages. All available quantitative phenotype data for
a strain is accessible from the RGD strain report page’s phenotype profile. In the section labeled “Phenotype Values via PhenoMiner”, select a
CMO term to view values for that strain.
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requests for inclusion in the ontologies and/or to suggest
modifications and improvements to the vocabularies.
Those wishing to submit such requests and suggestions
can do so using the “Contact Us” link at the top of the
RGD webpages [1] or the contact information supplied
on the appropriate BioPortal ontology description pages
[32]. Plans are underway to implement tracking soft-
ware, such as a SourceForge web page [33], to facilitate
this process.
Beyond RGD and the Animal QTLdb, the CMO,
MMO, and XCO ontologies and the associated QTL
annotation data are being used by researchers and other
databases via the freely-accessible RGD ftp site. In the
past six months, each of the ontologies has been
downloaded from the site between 190 and 314 times
(CMO: 314 requests; MMO: 211 requests; XCO: 190
requests). The total number of downloads of the data
annotation files were 71 for the CMO, 68 for the MMO,
and 67 for the XCO. Analysis of the ftp logs shows that
the file requests originate from a variety of institutions
including universities, medical schools, government
institutes and pharmaceutical companies, and from loca-
tions in the United States, Europe and Asia, demonstra-
ting the utility of both the ontologies themselves and the
associated annotations.
Although these ontologies were originally designed to
be used together, they also have utility individually. Onesuch example was recently demonstrated at the 4th
International Conference on Biomedical Ontology
where Goldfain et al. presented their work on the use
of ontologies to contextualize the measurement of
vital signs in individuals [34]. They use a subset of
the XCO to incorporate conditions such as “standing
position” (XCO:0000083).
For researchers interested in using the ontologies or
the associated data, or in submitting their own data for
incorporation into the data set, help is available on the
RGD website. Recently updated help pages [35] give
information on ontologies in general and their use at
RGD, as well as detailed instructions on the use of the
PhenoMiner tool, the Phenotypes and Models portal,
and the QTL report pages. Tutorial videos such as the
“Introduction to the RGD Phenotypes and Models
Portal” video [36] demonstrate step-by-step the use of
specific tools. The RGD “Introduction to Biomedical
Ontologies” tutorial series [37] is geared toward the
“ontology novice” and gives basic information about
what an ontology is and how it might be used. Finally,
help is always available by contacting the RGD curators
and developers via the “Contact Us” link at the top and
bottom of any RGD web page [1].
Future directions
There are continuing efforts to standardize both the struc-
ture and content of the ontologies. Future development
AB
Figure 4 Use of the CMO, MMO, XCO, VT, and RS ontologies to annotate RGD QTLs. The RS Ontology (A) and the CMO, MMO, XCO, and
VT Ontologies (B) are used at the Rat Genome Database to standardize the presentation of the rat strains crossed, the specific measurement that
was made, the method that was used to make that measurement, the conditions under which the measurement was made, and the specific trait
that was measured, respectively. Annotations are assigned an evidence code of “IED” or “inferred from experimental data” to indicate the type of
evidence (i.e., experimental) which supports the use of these terms.
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semantic reasoners, as well as continuing consulta-
tions with domain experts to more systematically fill
in gaps. Also, in the early stages of development, a
number of instrumentation terms were included as
measurement methods, for example, “oral thermom-
eter, digital” (MMO:0000196) [19]. However, this term
for an object was an is_a subclass of “thermometry”,
a method, creating an obvious problem since an ob-
ject is not a method. Work is underway to review the
ontologies both manually and through the use of
reasoners to find and correct these types of logical
inconsistencies.
Efforts are also underway to add systematic cross
referencing from CMO, MMO and XCO terms to rela-
ted concepts in other ontologies. As previously men-
tioned, cross references from XCO terms to ChEBI have
already been added. Going forward, we anticipate adding
similar cross references to ontologies related to disease,
cell types, and anatomy. Results from NCBO’s Mappings
tool [38,39] will be used as a starting point for finding
and documenting such inter-ontology relationships. Inaddition, we are investigating algorithms which may en-
able us to map between related terms even when the
terms do not use identical text.
In keeping with the common practice for ontology
development, the terms, class definitions and structure
of these ontologies will be reviewed yearly or as needed
to ensure that they remain up to date with advances in
the associated research domains and that they conform
to both initial and newly identified development require-
ments [40]. As the number of collaborating domain
experts for the development of these ontologies grows,
regular discussions with those collaborators will be sched-
uled to review terms, ontology structure and definitions.
Our location at the Medical College of Wisconsin is ideal
in this respect since MCW houses a large and varied com-
munity of basic rat researchers, clinical researchers and
clinicians. Such collaborations have already helped us
improve the ontologies.
Finally, in order to make these ontologies usable for
tools and software designed for OWL-formatted vocabu-
laries, we will make the CMO, MMO and XCO available
in the OWL format in the near future.
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Development of the three ontologies has been essential
for the integration of complex phenotype data at RGD.
Annotations derived from both high-throughput data
and a wide variety of literature-derived QTL data have
been incorporated using these ontologies. Increases in
the scope of the data being curated through inclusion of
studies from diverse areas of research have necessitated
substantial increases in the size and scope of all three
ontologies. The data used for the original development
of these ontologies was heavily weighted toward cardio-
vascular traits and related phenotypes. High-throughput
data from a subset of the Program for Genomic Applica-
tions data (PGA) [6,7] and standard phenotypes from
the National BioResource Project for the Rat in Kyoto,
Japan [8] steered development of the ontologies in this
direction. More recently, incorporation of data from
QTL studies as diverse as alcohol intake, cancer suscep-
tibility, limb length, joint inflammation, and movement
and behavior, as well as collaboration with the Animal
QTLdb, have prompted major expansion of the onto-
logies [5].
Recent advances in both the ontologies themselves
and their application have demonstrated the utility of
these vocabularies for facilitating the incorporation of
data from diverse sources. The use of multiple ontol-
ogies to describe individual data types across multiple
studies serves to integrate the data while maintaining
the aspects that are unique to each study or each mea-
surement. This has been demonstrated by RGD’s
PhenoMiner data and by annotation of QTL records at
RGD and the Animal QTLdb. Measurements, methods
and/or conditions are often shared across studies and
even across species. For instance, blood chemistry mea-
surements such as blood cholesterol level, blood glucose
level, and hematocrit are available for species from
human to chicken. The use of ontologies such as the
CMO allows querying of records for multiple species
across multiple databases. This cross-species use of
shared ontologies gives researchers the ability to access
data that previously might have been considered unre-
lated but is now revealed to be both related and import-
ant to consider.
“Ontology development is necessarily an iterative
process”, as one tutorial on ontology development put
it [41]. This paper describes the most recent iteration
of the development process for the Clinical Measure-
ment, Measurement Method, and Experimental Condi-
tion Ontologies. As the development process continues,
new concepts are continually being added and applica-
tion of these ontologies is continually expanding,
resulting in a greater ability to integrate, consolidate,
and compare phenotypic measurement data from di-
verse sources.Methods
The Clinical Measurement Ontology, Measurement
Method Ontology, and Experimental Condition Ontology
are being developed using the Open Biomedical Ontology
(OBO) format. The OBO-Edit software [42] is utilized to
add, move, merge, and delete terms as needed. This tool
also provides quality control for violations of the accepted
best practices for ontology development. Such checking is
utilized to find and correct such violations.
The need for new terms is established through a
collaborative process within and between the groups at
RGD and Animal QTLdb. As curation of new and
existing research articles proceeds, the existing vocabu-
laries are examined before a new term request is made.
If none of the existing terms is deemed appropriate for
use, a request is logged for one or more new terms.
Term requests are further reviewed by the ontology
developer to ensure the format and wording of the
putative new term agrees with pre-existing standards.
Literature searches, general internet searches, and consul-
tations with domain experts are utilized to establish the
proper placement of new terms and the construction of
both standardized and individual term definitions.
Ontology files are exported from OBO-Edit and
uploaded to the NCBO BioPortal site [32,43-45] and
RGD’s ftp site [46] as needed. During the upload pro-
cess, version numbers are incremented and the new
version numbers added to the file headers.
These ontologies are freely available for download




from the RGD ftp site at ftp://rgd.mcw.edu/pub/ontology/.Additional files
Additional file 1: Standard definition fragments. Additional file 1 is a
plain text (i.e., .txt file) list of definition fragments which are used to
construct standardized definitions for ontology terms. Each entry
contains the text of the word or phrase being defined, the definition, and
the definition source in the standardized format for source URIs.
Additional file 2: Standard sources for term definitions. Additional
file 2 is a plain text (i.e., .txt file) list of definition sources in the current
standardized URI format. Sources include clinical and veterinary texts,
standard medical and general dictionaries, websites, and review articles.
In addition to these “reusable” sources, research and review articles
covering specific details of measurements, methods or conditions are
used in some cases.
Additional file 3: Systematic versioning of ontology files. Additional
file 3 is a pdf version of the header of the CMO ontology file. The data-
version tag in the ontology file header, or metadata, shows the version
number of that file. Minor version number changes, e.g., 2.1 to 2.2,
indicate ongoing ontology development such as addition of new terms
and definitions. Major version number changes such as 1.x to 2.0 indicate
global changes to the ontology or major changes to its structure.
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